Fresenius Medical Care accelerates the second tranche of its EUR 1 billion share buyback program with around EUR 415 million repurchase planned

Rhea-AI Summary

Fresenius Medical Care (NYSE:FMS) will accelerate the second tranche of its EUR 1 billion share buyback program and intends to repurchase around EUR 415 million of its own shares from January 12 to May 8, 2026. The first tranche was completed ahead of schedule on December 29, 2025, and the company expects the full program to be completed in less than a year under its FME Reignite capital allocation framework. Management attributes the acceleration to strong cash-flow generation and continued business momentum. Regular progress updates will be provided on the company's investor website.

Positive

• Total share buyback program of EUR 1 billion
• Second tranche repurchase planned for ~EUR 415 million
• Repurchase window: Jan 12–May 8, 2026
• First tranche completed early on Dec 29, 2025
• Program expected completed in less than a year, accelerating capital return

Negative

• None.

News Market Reaction – FMS

+1.36%

+1.36% Session close to close

In the Jan 9 session, FMS gained 1.36%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement accelerates completion of Fresenius Medical Care’s EUR 1 billion buyback, with a s...

Analysis

This announcement accelerates completion of Fresenius Medical Care’s EUR 1 billion buyback, with a second tranche of about EUR 415 million scheduled through May 8, 2026. It builds on prior capital allocation moves under the FME Reignite strategy and follows earlier buyback disclosures. Investors may watch actual repurchase volumes, future earnings reports, and updates on business momentum to assess how effectively this program supports long-term shareholder value.

Key Figures

Total buyback program: EUR 1 billion Second tranche size: EUR 415 million Second tranche end date: May 8, 2026 +4 more

7 metrics

Total buyback program EUR 1 billion Overall share repurchase volume under FME Reignite strategy

Second tranche size EUR 415 million Planned repurchases from Jan 12 to May 8, 2026

Second tranche end date May 8, 2026 Expected completion of current buyback tranche

Program completion window Less than a year Expected time to complete EUR 1 billion buyback

Global dialysis patients 4.2 million Number of patients worldwide regularly undergoing dialysis

Company clinics 3,628 clinics Fresenius Medical Care dialysis clinic network

Patients treated 294,000 patients Patients treated in Fresenius Medical Care clinics

Historical Context

5 past events · Latest: Dec 10 (Positive)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Dec 10	Management change	Positive	+3.0%	New Global Chief Medical Officer appointed as part of planned transition.
Nov 04	Earnings and buyback	Positive	-7.8%	Strong Q3 2025 growth and profitability with initial EUR 1.0bn buyback announced.
Oct 30	Clinical/AI update	Positive	-0.8%	AI and hemodiafiltration data presented at ASN Kidney Week 2025.
Oct 01	Management change	Positive	+1.1%	New board member and CEO for Care Enablement effective January 2026.
Sep 18	Strategy/VBC update	Positive	-0.4%	Higher Interwell Health ownership and new VBC segment leader announced.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Positive strategic and financial news has often seen mixed or negative immediate price reactions, indicating occasional divergence between fundamentals and near-term trading.

Recent Company History

Over the past months, Fresenius Medical Care reported strong Q3 2025 earnings with buyback initiation, advanced its FME Reignite strategy via Interwell Health, and announced several leadership changes. Despite generally positive strategic and financial updates, share reactions were mixed, with some declines following good news. The current accelerated EUR 1 billion buyback fits the ongoing capital allocation and VBC expansion narrative highlighted in prior announcements.

Key Terms

share buyback, capital markets day, capital allocation framework, forward-looking statements, +3 more

7 terms

share buyback financial

"Fresenius Medical Care accelerates its share buyback program and start the repurchase"

A share buyback is when a company uses its cash to purchase its own stock from the market, which reduces the number of shares available to other investors. Think of it like a bakery buying back some of its own cookies so the remaining cookies are a bigger slice of the business; buybacks can raise per-share earnings and ownership stakes and signal management’s confidence, but they also use cash that could have been spent on growth or dividends.

View in glossary

capital markets day financial

"The program – presented during the company's Capital Markets Day on June 17, 2025"

A capital markets day is a scheduled event where a company presents its long-term strategy, financial plans and performance targets directly to investors, analysts and lenders. Think of it as a roadmap meeting where management shows how they plan to grow and use money; investors watch closely because the details can change expectations about future profits, risk and the stock’s value.

capital allocation framework financial

"part of the FME capital allocation framework within the 'FME Reignite' strategy"

A capital allocation framework is a set of guiding principles that a company uses to decide how to distribute its financial resources among various needs, such as investing in growth, paying dividends, or reducing debt. It helps ensure that the company's money is used efficiently to create value over time. For investors, understanding this framework offers insight into how a company plans to grow and manage its finances sustainably.

forward-looking statements regulatory

"This release contains forward-looking statements that are subject to various risks"

Forward-looking statements are predictions or plans that companies share about what they expect to happen in the future, like estimating sales or profits. They matter because they help investors understand a company's outlook, but since they are based on guesses and assumptions, they can sometimes be wrong.

dialysis medical

"around 4.2 million patients worldwide regularly undergo dialysis treatment"

Dialysis is a medical treatment that cleans the blood and removes extra fluid when the kidneys can no longer do that job, using a machine or a filtered solution much like an external water filter for the body. It matters to investors because dialysis creates steady demand for specialized clinics, machines, supplies and drugs, driving predictable revenue streams, capital and regulatory risks, and long-term patient volumes that affect healthcare company valuations.

renal diseases medical

"provider of products and services for individuals with renal diseases of which"

Renal diseases are conditions that damage the kidneys’ ability to filter waste, balance fluids, and regulate blood pressure, ranging from mild impairment to kidney failure that may require dialysis or transplant. For investors, these diseases drive demand for diagnostics, medicines, medical devices, and long-term care—think of kidneys as a home’s plumbing: when they fail, products and treatments to repair or replace that system become commercially important and can affect company revenues and regulatory scrutiny.

dialyzers medical

"leading provider of dialysis products such as dialysis machines and dialyzers"

Dialyzers are medical devices that act like an artificial kidney, filtering waste and excess fluid from the blood for patients with kidney failure. Think of them as a specialized water filter for the bloodstream; they are consumable components used each dialysis session and thus drive recurring revenue, supply chain needs, and regulatory scrutiny—factors that can directly affect healthcare companies’ sales, margins, and investor risk.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

• The second tranche of the share buyback is expected to be executed by May 8, 2026
• The share buyback program with a total volume of EUR 1 billion is expected to be completed in less than a year, significantly earlier than originally planned

BAD HOMBURG, Germany, Jan. 9, 2026 /PRNewswire/ -- Fresenius Medical Care (FME), the world's leading provider of products and services for individuals with renal disease, will accelerate its share buyback program and start the repurchase of the second tranche. The program – presented during the company's Capital Markets Day on June 17, 2025 – has a total volume of EUR 1 billion. Under the second tranche, the company plans to repurchase its own shares for a total amount of around EUR 415 million from January 12 to May 8, 2026.

The first tranche of the company's share buyback program was completed ahead of schedule on December 29, 2025. The share buyback program, which is part of the FME capital allocation framework within the 'FME Reignite' strategy, is expected to be completed significantly earlier than originally planned, in less than a year.

Helen Giza, CEO and Chair of the Management Board, said, "The successful acceleration of our EUR 1 billion share buyback program is supported by our strong financial performance and consistent execution against our 'FME Reignite' strategy, with a focus on value creation and delivering returns to our shareholders."

"Our strong cash-flow generation on the back of continued business momentum enables an acceleration of our share buyback program, demonstrating the effectiveness of our new capital allocation framework," said Martin Fischer, CFO of Fresenius Medical Care.

FME will provide regular updates on the progress of the share buyback program at https://freseniusmedicalcare.com/en/investors/shares/share-buy-back/

About Fresenius Medical Care:
Fresenius Medical Care is the world's leading provider of products and services for individuals with renal diseases of which around 4.2 million patients worldwide regularly undergo dialysis treatment. Through its network of 3,628 dialysis clinics, Fresenius Medical Care provides dialysis treatments for approximately. 294,000 patients around the globe. Fresenius Medical Care is also the leading provider of dialysis products such as dialysis machines and dialyzers. Fresenius Medical Care is listed on the Frankfurt Stock Exchange (FME) and on the New York Stock Exchange (FMS).

For more information visit the Company's website at www.freseniusmedicalcare.com.

Disclaimer:
This release contains forward-looking statements that are subject to various risks and uncertainties. Actual results could differ materially from those described in these forward-looking statements due to various factors, including, but not limited to, changes in business, economic and competitive conditions, legal changes, regulatory approvals, results of clinical studies, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. These and other risks and uncertainties are detailed in Fresenius Medical Care's reports filed with the U.S. Securities and Exchange Commission. Fresenius Medical Care does not undertake any responsibility to update the forward-looking statements in this release.

Media contact
Christine Peters
T +49 160 60 66 770
christine.peters@freseniusmedicalcare.com

Contact for analysts and investors
Dr. Dominik Heger
T +49 6172 609 2601
dominik.heger@freseniusmedicalcare.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/fresenius-medical-care-accelerates-the-second-tranche-of-its-eur-1-billion-share-buyback-program-with-around-eur-415-million-repurchase-planned-302657278.html

SOURCE Fresenius Medical Care Holdings, Inc.

FAQ

What does Fresenius Medical Care (FMS) plan to repurchase in the second tranche?

The company plans to repurchase around EUR 415 million of its own shares in the second tranche.

When will FMS execute the second tranche repurchases?

Repurchases are planned from January 12 to May 8, 2026.

When was the first tranche of the FMS EUR 1 billion buyback completed?

The first tranche was completed ahead of schedule on December 29, 2025.

How long will it take FMS to complete the EUR 1 billion buyback program?

The company expects to complete the full program in less than a year.

Why is FMS accelerating its share buyback program?

Management cites strong cash-flow generation and continued business momentum under the FME Reignite strategy.

Where can investors track progress of the FMS share buyback?

Regular updates will be posted on the company's investor website at the share buy-back section.